ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado.
The Company’s lead investigational product is Gencaro™ (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic heart failure, was accepted for filing by the U.S. Food and Drug Administration in September, 2008. On May 31, 2009, the Company received a Complete Response Letter from the FDA.
ARCA biopharma is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development. Applying this approach to the development of Gencaro, ARCA scientists have discovered genetic variations in two cardiac receptors that interact with Gencaro’s unique pharmacology. ARCA biopharma believes that these variations have the potential to help predict patient response to Gencaro.
In January, 2009, ARCA biopharma merged with Nuvelo, Inc., forming a new cardiovascular company with increased resources, expertise, and a significant developmental pipeline. ARCA biopharma, Inc. trades on the Nasdaq Global Market, under the symbol ABIO.
1. Gencaro tradename is also under review with the FDA.
